Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Comment by prophetoffactzon Aug 29, 2024 4:57pm
66 Views
Post# 36201916

RE:RE:Perplexity Ai: The conclusion...

RE:RE:Perplexity Ai: The conclusion...
Stinzo wrote: The conclusion is that the stock price sank, meaning the market or people do not believe in this macimorelin making any money. Ask your AI why no one is buying shares if the conclusion is so compelling. 


CSCI still hasn't released a new post-merger plan for the company with the Q2 financials press release saying a "fulsome" update is coming "shortly". There is no plan prioritizing certain assets released to the public yet. We don't know when the company will run out of money and have to finance and what material valuation catalysts will be reached with current funding. There has never been any preclinical or clinical data released for the avenanthramide pill. PGX only works at the 10L pilot scale with the 5X and 10X scale-up to come. They are reviewing data for other programs and have had regulatory meetings scheduled to define a path forward. There is no path forward as the company appears to be rapidly burning money. There is no analyst coverage.

This company is still a mystery burning money. Half the company was trading on the TSX-V and Americans likely have little to no understanding. The stock is owned by retail with little inclination to understand the assets.

That diagnostic trial was to be the basis for a licensing deal with a significant upfront payment, in my opinion, and that was to finance the path forward. Unfortunately the path forward is clouded now and they are going to have to adjust their plan.

I believe the "fulsome" update that is expected is to be the launch of the new company on NASDAQ.  

<< Previous
Bullboard Posts
Next >>